Trinity Biotech Partners with University at Buffalo to Develop Sjögren’s Syndrome Biomarkers
Event summary
- Trinity Biotech has entered a collaboration with the University at Buffalo to commercialize novel biomarkers for Sjögren’s Syndrome, an underdiagnosed autoimmune disease.
- The partnership leverages UB’s proprietary biomarkers and Trinity Biotech’s NYSDOH-approved reference laboratory for commercialization.
- The collaboration aims to improve diagnostic accuracy and speed for Sjögren’s Syndrome, particularly in early-stage or seronegative patients.
- UB CAT provided applied R&D funding to support the early stages of product development.
- Trinity Biotech expects the collaboration to expand its pipeline of autoimmune and immunology-focused diagnostic innovations.
The big picture
Trinity Biotech’s collaboration with the University at Buffalo aligns with its strategic pivot toward specialty autoimmune and metabolic diagnostics. The partnership underscores the growing emphasis on precision diagnostics and the unmet clinical need for earlier and more accurate detection of Sjögren’s Syndrome. This move positions Trinity Biotech to capitalize on the expanding market for high-value diagnostic tests, leveraging its enhanced U.S. reference laboratory infrastructure and proprietary biomarker development partnerships.
What we're watching
- Diagnostic Innovation
- How the commercialization of these biomarkers will impact the diagnostic landscape for Sjögren’s Syndrome and other autoimmune diseases.
- Market Expansion
- Whether Trinity Biotech can sustain its strategic shift toward higher-value, innovation-led diagnostics in the U.S. market.
- Execution Risk
- The pace at which Trinity Biotech can integrate and commercialize the biomarkers through its reference laboratory.
Related topics